MediGene gets research grant to expand EndoTAG vascular technology

By Elaine Rigoli

Tampa, Fla., June 23 - MediGene AG has received a research grant of about €0.4 million from the German Federal Ministry of Education and Research for the further development of the EndoTAG platform.

Up to now, MediGene said it has been developing a drug for the treatment of various types of cancer, based on the EndoTAG technology.

However, the funds now granted are intended for the development of EndoTAG for the treatment of other diseases associated with pathological formation of new blood vessels. The funds will be provided over the next two years.

In March, the Bavarian Research Foundation granted €1.4 million to support the development of EndoTAG in other indications.

MediGene is a German-American biotechnology company located in Martinsried, Germany, and San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.